Valerie Dao, A. Oppetit, Hugues Pellerin, E. Chamboredon, Aveline Aouidad, G. Bronsard, Nicolas Campelo, David Cohen
{"title":"Are adolescents engaged in violent radicalization suicidal?","authors":"Valerie Dao, A. Oppetit, Hugues Pellerin, E. Chamboredon, Aveline Aouidad, G. Bronsard, Nicolas Campelo, David Cohen","doi":"10.2174/2210676613666230801153633","DOIUrl":"https://doi.org/10.2174/2210676613666230801153633","url":null,"abstract":"\u0000\u0000Radicalization among adolescents is a rising phenomenon that has become a public health concern in Europe. According to some authors, violent radicalization by resorting to self-violence could be a form of suicidal behavior. However, evidence-based studies to support this assertion are lacking.\u0000\u0000\u0000\u0000The aim of this study was to investigate the issue of suicidality among adolescents engaged in violent radicalization.\u0000\u0000\u0000\u0000We compared a group of radicalized adolescents convicted of criminal association to commit terrorism (AMT) in France (N=15) with hospitalized adolescents who have attempted to end their lives (N=320). This comparative study is based on two samples from two studies that used the same instruments to assess psychiatric diagnoses, suicide risk, reasons for living, and coping.\u0000\u0000\u0000\u0000AMT adolescents were significantly less suicidal and less depressive/hopeless than adolescents with suicide attempts (SAs). AMT adolescents showed fewer instances of depressive and borderline personality disorders but more manic and psychotic episodes than SA adolescents. They also had much more efficient coping strategies than SA adolescents, especially for the following strategies: seeking professional help, relational support and spiritual support. All the subscores of the reasons for the living scale were significantly higher for AMT adolescents than for SA individuals, apart from the subscore on peer acceptance and support.\u0000\u0000\u0000\u0000Adolescents engaged in violent radicalization cannot be considered suicidal adolescents who have found an opportunity to end their lives through the process of radicalization. Understanding this phenomenon within a social, political and cultural context is necessary.\u0000","PeriodicalId":43326,"journal":{"name":"Adolescent Psychiatry","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44459694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joshua White, T. Kohn, M. Rivero, A. Muthigi, Jamie Thomas, A. Ghomeshi, Francis Petrella, David Miller, M. Rueda-Lara, Ranjith Ramasamy
{"title":"The Impact of COVID-19 on Psychotropic Medication Prescriptions in Adolescents: Analysis of a Federated Research Network","authors":"Joshua White, T. Kohn, M. Rivero, A. Muthigi, Jamie Thomas, A. Ghomeshi, Francis Petrella, David Miller, M. Rueda-Lara, Ranjith Ramasamy","doi":"10.2174/2210676613666230619142223","DOIUrl":"https://doi.org/10.2174/2210676613666230619142223","url":null,"abstract":"\u0000\u0000COVID-19 pandemic restrictions resulted in psychosocial stress and increased potential for psychiatric disorders in the adolescent population. Adolescent psychiatric disorders are increasingly managed with psychotropic medications. We aimed to evaluate the first-time prescription rates of psychotropic medications—antidepressants, antipsychotics, hypnotics, sedatives, mood stabilizers, and psychostimulants—in adolescent patients during the COVID-19 pandemic compared to the years immediately prior.\u0000\u0000\u0000\u0000We utilized electronic health records, claims data, and pharmaceutical data generated from 68 healthcare organizations stored within the TriNetX Research Network to conduct a retrospective matched cohort study. Adolescent patients aged 10-19 years presenting for outpatient evaluation were placed into two cohorts: 1) outpatient evaluation before (2017-2019) and 2) during (2020-2022) the COVID-19 pandemic. Patients with prior history of psychiatric disorders and/or prior use of psychotropic medications were excluded. The main outcome was first-time psychotropic medication prescription within 90 days of outpatient evaluation. We used propensity score matching with logistic regression to build cohorts of equal size based on covariates of interest.\u0000\u0000\u0000\u0000A total of 1,612,283 adolescents presenting before the COVID-19 pandemic and 1,008,161 adolescents presenting during the COVID-19 pandemic were identified. After matching on age, race/ethnicity, smoking status, and obesity status, a total of 1,005,408 adolescents were included in each cohort, each with an average age of 14.7 ± 2.84 years and 52% female and 48% male. The standardized differences between propensity scores were less than 0.1, suggesting a minimal difference between the two groups. Prescription rates for antipsychotics and benzodiazepines were increased for adolescents presenting during the pandemic (Risk Ratio (RR): 1.58, 95% confidence intervals (CI) 1.48-1.69). However, this group had decreased prescription rates for antidepressants (RR: 0.6, 95% CI 0.57-0.63), anxiolytics (RR: 0.78, 95% CI 0.75-0.81), psychostimulants (RR: 0.26, 95% CI 0.25-0.27), and mood stabilizers (RR: 0.44, 95% CI 0.39-0.49).\u0000\u0000\u0000\u0000Adolescents presenting for outpatient evaluation during the COVID-19 pandemic were prescribed antipsychotics and benzodiazepines at an increased rate relative to the years immediately prior, suggesting an increased need for sedation in this patient population. Given reduced access to care during the COVID-19 pandemic, the decreased prescription rate observed for other psychotropic medication classes does not necessarily reflect a decreased incidence of the associated psychiatric disorders.\u0000","PeriodicalId":43326,"journal":{"name":"Adolescent Psychiatry","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44946354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Baseline and Outcome Comparison of Adolescents in Treatment for Opioid and Non-opioid Use Disorder","authors":"M. LaCasse, Ryan M. Loh, C. Thurstone","doi":"10.2174/2210676613666230503094501","DOIUrl":"https://doi.org/10.2174/2210676613666230503094501","url":null,"abstract":"\u0000\u0000In the current opioid epidemic, little is known about\u0000differences in treatment structure for youth with opioid use disorder (OUD) and\u0000youth with other substance use disorders.\u0000\u0000\u0000\u0000This study analyzed baseline characteristics and outcome data\u0000comparing youth who suffer from OUD vs. those with other substance use disorders\u0000in an urban Denver, Colorado clinic.\u0000\u0000\u0000\u0000A retrospective cohort review was conducted, analyzing clinical data\u0000between February 2017 and March 2021. Two groups were created and compared:\u0000those with OUD (n = 59) and those with other substance use disorders (n = 417).\u0000The primary outcome variable was achieving a negative urine drug screen within 16\u0000weeks of baseline assessment. We hypothesized that there would be no difference\u0000between the groups in the primary outcome variable.\u0000\u0000\u0000\u0000Youth with OUD were slightly older and had more co-morbid stimulant\u0000use disorder. No difference between the groups was observed in achieving a\u0000negative urine drug screen within 16 weeks.\u0000\u0000\u0000\u0000A multimodal, generalized treatment approach yielded similar\u0000outcomes for those suffering from OUD compared to those with other substance\u0000use disorders. There might not need to be significant variances in treatment\u0000approach depending on the specific substance use disorder.\u0000","PeriodicalId":43326,"journal":{"name":"Adolescent Psychiatry","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42749499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sleep Disturbances in Children and Adolescents with Autism Spectrum Disorder:\u0000An Overview for Clinicians","authors":"Mayank Gupta, Nihit Gupta, Yuli Fradkin, T. Petti","doi":"10.2174/2210676613666230126115646","DOIUrl":"https://doi.org/10.2174/2210676613666230126115646","url":null,"abstract":"\u0000\u0000Sleep disorders in autism spectrum disorders (ASD/SD) are distinct, broad, and highly variable clinical entities that ubiquitously affect core symptomatology, development of comorbid disorders, and overall quality of life for affected children and families. High genetic predisposition and the presence of co-occurring disorders present significant challenges in assessment and appropriate interventions.\u0000\u0000\u0000\u0000The study aimed to review the best available evidence and address the clinical gaps in the knowledge about sleep disorders in children and adolescents with autism spectrum disorders.\u0000\u0000\u0000\u0000The review provides a comprehensive literature search of 1622 articles and summarizes 110 selected for empirical evidence to methodically consider critical aspects of sleep disorders in ASD for informing clinicians of useful information.\u0000\u0000\u0000\u0000Clinicians have insufficient guidance and support to effectively manage sleep disruptions in ASD youth in practice. Prevalence of sleep disruption in ASD, close to 80%, is characterized by unique subtypes, including but not limited to obstructive sleep apnea, circadian rhythm disorders, and sleep-related movement disorders. Greater awareness of sleep disruption, its neurodevelopmental basis, scope, and impact allows for improved treatment and prevention efforts of these conditions, and is critical for clinical practice and future research. The bidirectional nature of disruptive sleep and ASD is considered a major area requiring further clarification.\u0000\u0000\u0000\u0000Clinician-friendly screening tools are needed for everyday office practice to identify ASD/SD conditions and interventions, and mitigate harmful effects. Psychoeducational and cognitive-behavioral approaches for improving and supporting healthy sleep hygiene, considered the first line of treatment, are detailed. The weak database for the use of psychopharmacologic agents is summarized, and the strength of prescribing prolonged-release melatonin for optimal results is described. The promise of other medications is discussed.\u0000","PeriodicalId":43326,"journal":{"name":"Adolescent Psychiatry","volume":"1 1","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41593218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}